15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 单与联合治疗小儿乙肝:哪一个更好?
查看: 394|回复: 1
go

单与联合治疗小儿乙肝:哪一个更好? [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2015-10-9 15:34 |只看该作者 |倒序浏览 |打印
Bryant Furlow
October 08, 2015
Mono- vs. Combination Therapy for Pediatric Hep B: Which is Better?



SAN DIEGO, CA—No significant differences were found between lamivudine monotherapy, interferon-alpha monotherapy, or combination lamivudine + interferon therapy among treatment-naïve children with chronic hepatitis B infection, but spontaneous seroconversion was more common among older children, reported authors of a retrospective study presented at IDWeek 2015.

“No statistically significant difference was found in terms of response to treatment between the three different treatments,” reported Emine Kocabas, MD, a professor at Çukurova University in Adana, Turkey, and coauthors.

Dr. Kocabas and coauthors evaluated 403 treatment-naïve children with chronic hepatitis B infection who were followed up at outpatient pediatric infectious disease clinics from January 2004 to December 2013. The presence of hepatitis B in families was 82.6%.

Of the 403 children enrolled, 31.2% (n=126) of children experienced spontaneous seroconversion during their 10-year follow-up period, Dr. Kocabas reported. Spontaneous seroconversion was associated with older age (median age at diagnosis, 9.9 years vs. 8.5 years; P<0.01), Dr. Kocabas said.

The three treatment groups consisted of monotherapy (Group I and Group II) and combination therapy (Group III). In Group I, 35 patients received interferon-alpha (IFN-α) monotherapy for 6 months; in Group II, 29 patients received lamivudine monotherapy (4mg/kg) for 12 months; and the 101 patients in Group III received lamivudine for 12 months, with IFN-α for the first 6 months. Patients in the study arms had significant baseline differences in mean age (P<0.05), mean ALT (P<0.01), and fibrosis score (P<0.01), Kocabas reported.

No statistically significant difference was observed in responses between these 3 regimens.

“The potential benefits of these 3 therapeutic regimens need to be further investigated to confirm these results with larger number of patients,” Dr. Kocabas concluded.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2015-10-9 15:34 |只看该作者
科比Furlow
2015年10月8日
单与联合治疗小儿乙肝:哪一个更好?



SAN DIEGO,CA-没有被拉米夫定单药治疗,干扰素α单药治疗,或联合拉米夫定+干扰素治疗的发现其中初治儿童慢性乙肝感染显著差异,但自发的血清学转换是其中年龄较大的儿童多见,报告的作者回顾性研究,提出了在2015年IDWeek。

“无统计学显著差异,在应对三种不同的处理之间的治疗方面,”报告袆峰Kocabas,医学博士,在Çukurova大学在阿达纳,土耳其和合作者教授。

Kocabas博士及其合作者评估403治疗初治儿童慢性乙肝感染谁,随访在门诊儿科感染性疾病门诊,从2004年1月2013年12月在家庭乙肝的存在为82.6%。

403儿童入学,31.2%(126例)儿童在其10年的随访期间经历了自发血清转换,Kocabas博士报告。自发血清转换与年龄有关(位年龄为9.9岁vs.8.5年; P <0.01),Kocabas博士说。

三个治疗组包括单药治疗(I组和II组)和联合治疗(组三)。在第一组,35例患者接受干扰素(IFN-α)单药治疗6个月;在第二组,29例患者接受拉米夫定单药治疗(4毫克/千克)为12个月;和101例第三组接受拉米夫定治疗12个月,IFN-α的前6个月。在研究组患者的平均年龄(P <0.05)显​​著基线差异,平均ALT(P <0.01),纤维化评分(P <0.01),Kocabas报道。

无统​​计学差异显著观察到这3个方案的反应。

“这3个治疗方案的潜在效益有待进一步研究,以确认这些结果具有较大的病人数,”Kocabas博士总结道。
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-2 22:27 , Processed in 0.012394 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.